^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

1968p - The clinical effect of concurrent oncogenic gene mutations in BRAF p.(V600E)-mutated NSCLC treated with dabrafenib and trametinib

Published date:
09/14/2020
Excerpt:
...advanced NSCLC patients before dabrafenib and trametinib treatment were included...A BRAF p.(V600E) was identified in 35 patients and a p.(V600_K601delinsE) was observed in one patient.Patients with and without concurrent mutations had a PFS of 20.3 and 10.2 months...The patient with a BRAF p.(V600_K601delinsE) responded to the treatment and had a PFS of 5 months.